Article Per Year (5 Year)
p-Index From 2021 - 2026
0.817
P-Index
This Author published in this journals
All Journal Narra J Narra X
Acharya, Yogesh
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Physics Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Narra X

 1 
Efficacy of acetazolamide and loop diuretics combinatorial therapy in congestive heart failure: A meta-analysis Duta , Teuku F.; Zulfa , Putri O.; Alina, Meulu; Henira, Najlaika; Tsurayya, Ghina; Fakri, Fajar; Acharya, Yogesh
Narra X Vol. 2 No. 1 (2024): April 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narrax.v2i1.124

Abstract

Acetazolamide, one of the carbonic anhydrase inhibitors, has been known to improve the efficacy of diuretic therapy in patients with in congestion heart failure. The aim this study was to investigate the effectiveness of acetazolamide when combined with loop diuretics in ameliorating diuresis and natriuresis in congestive heart failure using systematic review and meta-analysis. Randomized controlled trials (RCTs) and cohort studies were searched on PubMed, Scopus, and Embase on March 7, 2023, by using combinations of ‘acetazolamide’, ‘heart failure’ and along with their respective synonyms. The protocol had been registered on PROSPERO (CRD42023409864). The studies must investigate the effect of oral acetazolamide as the add-on to loop diuretic therapy to be included. Successful decongestion, natriuresis, and diuresis were set as the primary outcomes. The quality of the included studies was assessed using the Cochrane risk-of-bias tool for RCTs and Newcastle Ottawa Scale for observational studies. We identified 1176 titles in the initial search, and further reduced to five studies (three RCTs and two cohort studies) after in-depth screening. A total of 625 patients were recruited in the included studies published from 2015 to 2022. Results from meta-analysis revealed that acetazolamide and loop diuretics combination therapy ameliorated natriuresis (n=4; standardized means difference (SMD)=0.65; 95%CI: 0.07–1.24; p=0.03) and diuresis (n=2; SMD=0.29; 95%CI: 0.12–0.46; p=0.0009) when compared to loop diuretics alone. Acetazolamide and loop diuretics combinatorial therapy is efficacious in alleviating congestion in heart failure patients.
Essential oils for COVID-19 management: A systematic review of randomized controlled trials Duta, Teuku F.; Rizki, Diva R.; Purnama , Agnia; Rademaker, Marius; Wollina, Uwe; Acharya, Yogesh; Abdeen, Ziad; Rosa, Sandro G. V.; Nielsen, Henning B.; Subbaram, Kannan
Narra X Vol. 1 No. 2 (2023): August 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narrax.v1i2.84

Abstract

Essential oils can be a beneficial adjuvant therapy in managing coronavirus disease 2019 (COVID-19). This systematic review aims to evaluate the efficacy of essential oils in ameliorative COVID-19-related symptoms. Published studies reporting the efficacy of essential oils as adjuvant therapy for COVID-19 were screened on Scillit, Scopus, SciFinder, and PubMed (December 7th, 2022). Inclusion criteria include the randomized controlled trials (RCTs) participated by those diagnosed with COVID-19 and treated with essential oils as adjuvant therapy. Quality assessment was carried out using Cochrane ‘risk-of-bias’ 2.0 tool. A total of 2112 records were retrieved from the initial screening, which was reduced to four publications (n=344 individuals). The foregoing studies reported that essential oils could improve the recovery rate, alleviate post-COVID-19 fatigue, and prevent disease progression. Regarding their potential antiviral activity, better designed studies are needed. In conclusion, essential oils as adjuvant therapy are beneficial in ameliorating mild COVID-19 symptoms.
Efficacy of acetazolamide and loop diuretics combinatorial therapy in congestive heart failure: A meta-analysis Duta , Teuku F.; Zulfa , Putri O.; Alina, Meulu; Henira, Najlaika; Tsurayya, Ghina; Fakri, Fajar; Acharya, Yogesh
Narra X Vol. 2 No. 1 (2024): April 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narrax.v2i1.124

Abstract

Acetazolamide, one of the carbonic anhydrase inhibitors, has been known to improve the efficacy of diuretic therapy in patients with in congestion heart failure. The aim this study was to investigate the effectiveness of acetazolamide when combined with loop diuretics in ameliorating diuresis and natriuresis in congestive heart failure using systematic review and meta-analysis. Randomized controlled trials (RCTs) and cohort studies were searched on PubMed, Scopus, and Embase on March 7, 2023, by using combinations of ‘acetazolamide’, ‘heart failure’ and along with their respective synonyms. The protocol had been registered on PROSPERO (CRD42023409864). The studies must investigate the effect of oral acetazolamide as the add-on to loop diuretic therapy to be included. Successful decongestion, natriuresis, and diuresis were set as the primary outcomes. The quality of the included studies was assessed using the Cochrane risk-of-bias tool for RCTs and Newcastle Ottawa Scale for observational studies. We identified 1176 titles in the initial search, and further reduced to five studies (three RCTs and two cohort studies) after in-depth screening. A total of 625 patients were recruited in the included studies published from 2015 to 2022. Results from meta-analysis revealed that acetazolamide and loop diuretics combination therapy ameliorated natriuresis (n=4; standardized means difference (SMD): 0.65; 95%CI: 0.07–1.24; p=0.03) and diuresis (n=2; SMD: 0.29; 95%CI: 0.12–0.46; p=0.0009) when compared to loop diuretics alone. Acetazolamide and loop diuretics combinatorial therapy is efficacious in alleviating congestion in heart failure patients.
Co-Authors Abdeen, Ziad Alina, Meulu Anak Agung Dewi Megawati, Anak Agung Dewi Andri Frediansyah, Andri Bondarenko, Anastasia Chandran, Deepak Duta , Teuku F. Duta, Teuku F. Emran, Talha B. Fajar Fakri Fauzi Yusuf, Fauzi Firzan Nainu Harapan Harapan Henira, Najlaika Ikram, Aamer Iqhrammullah, Muhammad Khader, Yousef Kotfis, Katarzyna Koyanagi, Ai Kretchy, James-Paul Kurnia F. Jamil Lemu, Yohannes K. Mamada, Sukamto S. Memish, Ziad A. Nielsen, Henning B. Purnama, Agnia Rademaker, Marius Rizki, Diva R. Rosa, Sandro G. V. Sallam, Dina E. Sallam, Malik Sharun, Khan Smith, Lee Subbaram, Kannan Torres-Roman, J. Smith Tsurayya, Ghina Vento, Sandro Wollina, Uwe Yufika, Amanda Zulfa , Putri O.